Martina V, Miola C, Maccario M, Talliano M, Arvat E, Ghigo E, Camanni F
Department of Clinical Pathophysiology, University, of Turin, Italy.
Horm Metab Res. 1992 Nov;24(11):520-3. doi: 10.1055/s-2007-1003379.
Patients with type 1 diabetes mellitus (IDDM) show augmented GH secretion, which is implicated in the pathogenesis of microvascular complications. On the other hand, it is well known that beta-adrenergic receptors have inhibitory influence on GH secretion, likely via stimulation of hypothalamic somatostatin. Since the possibility of pharmacological suppression of GH secretion would be of value in IDDM, we investigated the effect of salbutamol (SAL, 4 mg orally at -60 min) on the GH response to GHRH (1 micrograms/kg iv at 0 min) in 6 well-controlled (mean HbA1c +/- SEM: 7.3 +/- 0.5%) patients with IDDM. Salbutamol was able to inhibit basal GH levels (p < 0.05) as well as to abolish the GHRH-induced GH rise. After SAL administration, a significant (p < 0.05) reduction of glucagon levels was also found. Our data show that the enhancement of beta 2 adrenergic activity by oral therapeutical doses of SAL inhibits basal and GHRH-stimulated GH secretion in patients with IDDM.
1型糖尿病（IDDM）患者的生长激素（GH）分泌增加，这与微血管并发症的发病机制有关。另一方面，众所周知，β-肾上腺素能受体可能通过刺激下丘脑生长抑素对GH分泌产生抑制作用。由于药物抑制GH分泌的可能性对IDDM具有重要意义，我们研究了沙丁胺醇（SAL，在-60分钟时口服4毫克）对6例血糖控制良好（平均糖化血红蛋白A1c +/- SEM：7.3 +/- 0.5%）的IDDM患者GH对生长激素释放激素（GHRH，在0分钟时静脉注射1微克/千克）反应的影响。沙丁胺醇能够抑制基础GH水平（p < 0.05），并消除GHRH诱导的GH升高。给予SAL后，还发现胰高血糖素水平显著降低（p < 0.05）。我们的数据表明，口服治疗剂量的SAL增强β2肾上腺素能活性可抑制IDDM患者的基础GH分泌以及GHRH刺激的GH分泌。
